CRYSTALLINE FORM OF JAK KINASE INHIBITOR BISULFATE AND A PREPARATION METHOD THEREOF

The present invention relates to a crystal form of JAK kinase inhibitor bisulfate and a preparation method thereof. In particular, the present invention relates to a type II crystal of (3 aR, 5 s, 6 aS ) -N- (3-methoxyl-1,2,4-thiadiazole-5-yl)-5-(methyl(7 H- pyrrolo[2,3- d ]pyrimi dine-4-yl)amino)he...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Sun, Piaoyang, Wu, Guaili, Zhang, Quanliang, Chen, Yongjiang, Shen, Lingjia
Format:	Patent
Sprache:	hrv ; eng
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to a crystal form of JAK kinase inhibitor bisulfate and a preparation method thereof. In particular, the present invention relates to a type II crystal of (3 aR, 5 s, 6 aS ) -N- (3-methoxyl-1,2,4-thiadiazole-5-yl)-5-(methyl(7 H- pyrrolo[2,3- d ]pyrimi dine-4-yl)amino)hexahydrocyclopenta[ c ]pyrrole-2(1 H )-formamide bisulfate and a preparation method thereof. The preparation method comprises crystallizing any crystal forms or amorphous compound of formula (I) solid in a single organic solvent or a mixed organic solvent to obtain a type II crystal form of a compound of formula (I). The type II crystal form of compound of formula (I) obtained by the present invention has a good crystal stability and chemical stability, and the used crystal solvent has a low toxicity and residue, which can be better used in clinical treatment.